Pharming (PHAR) Q3 2026 Earnings Call Transcript

Pharming Group reported Q3 revenue of $117.6 million, up 21% year over year, with operating profit up 89% to $29.9 million; adjusted operating profit was $35 million versus $16 million a year earlier. Management narrowed 2026 revenue guidance to $380 million–$390 million and reduced operating expense guidance to $310 million–$315 million, while Joenja revenue grew 58% and RUCONEST returned to growth. Results included a temporary $2 million–$3 million Joenja revenue pull-forward and early RUCONEST channel inventory; management also cited a prospective oral competitor and expects FALCON enrollment completion in the first half of 2027.

Analysis

Headline growth overstates the quarter’s underlying exit rate: RUCONEST benefited from channel inventory timing, while Joenja had $2–3 million pulled forward from Q4. The implied Q4 revenue range is therefore not just a seasonal comparison; it is a near-term test of whether patient demand can offset the unwind. For valuation, separate repeatable patient additions and retention from channel orders, FX gains, and the inventory impairment. The impairment also warrants verification in filings: determine whether it is isolated or signals recurring manufacturing yield or inventory-management risk.

The main near-term equity catalyst is the November CVID readout, but the investment case should not price management’s larger-population ambition as established value. A 20-patient, open-label study in a heterogeneous, selected group can provide a biological signal, not confirm registrational efficacy or commercial uptake. A consistent effect across lymphoproliferation and organ measures would improve the pipeline option value; mixed endpoints or safety concerns would expose the premium embedded in that narrative. Pediatric Joenja uptake is a smaller, more measurable growth driver, while the CEO search adds execution uncertainty.

Over 6–18 months, RUCONEST remains exposed to oral substitution despite management’s retention claims; the expected new oral entrant’s end-April 2027 FDA date is a catalyst for reassessing volume and pricing. Joenja’s expansion may offset erosion, but timing and patient identification matter. Cash reduces financing risk, not clinical or commercial risk. Without valuation and share-price context, the quarter alone does not justify chasing a gap higher.

Key Decisions for Investors

• Do not chase the earnings reaction on headline growth. Track Q4 revenue against the $100–110 million implied range, but prioritize underlying patient volumes and channel inventory normalization over reported sales alone.
• Treat PHAR as a catalyst-driven watch ahead of the November CVID data. Prefer initiating or adding only after reviewing endpoint-level results; require a reasonably consistent efficacy signal and acceptable safety before assigning meaningful value to the broader indication.
• If CVID results are supportive, consider a staged long PHAR position rather than a pre-readout options bet; if results are inconsistent or fail to show a clear lymphoproliferation signal, avoid adding and reassess the pipeline valuation. No numeric target is warranted without valuation data.
• Monitor the CEO appointment, impairment disclosures, pediatric paid-patient additions, and RUCONEST demand separately. Revisit the long thesis if normalized RUCONEST volumes resume declines or if the 2027 oral-competitor review materially worsens management’s expected patient-retention outlook.